Partial Blocks of Rectus Femoris and Soleus With Botulinum Toxin Type A (Xeomin®) to Improve Gait in Hemiparesis "GENUFLEX"

Recruiting

Phase 2 Results N/A

Summary of Purpose

The most common motor deficiency after stroke or traumatic brain injury is hemiparesis. Most hemiparetic patients recover walking, but rarely with a speed permitting easy ambulation outdoors with family or friends. One of the mechanisms of gait impairment in hemiparesis is insufficient active hip flexion during swing phase, which leads to insufficient ground clearing at swing phase, with associated gait slowness...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 13 April 2017.

1 Dec 2014 23 Dec 2016 1 Nov 2017 1 Dec 2018 1 Dec 2016 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

Not available

Contacts

  • Jean-Michel GRACIES, MD, PhD